Table 3.
Studies on clinical significance of E2F1 expression in NSCLC
Study/year1 | Patient number | Adenocarcinoma/SCC | Assay used | Incidence of E2F1 overexpression | Survival difference |
---|---|---|---|---|---|
Volm/1998 |
96 |
0/96 |
IHC |
24% |
No |
Gorgoulis/2002 |
77 |
37/37 |
IHC |
49% |
Yes |
Huang/2007 |
127 |
63/58 |
Quantitative RT-PCR |
40% |
Yes |
Hung/2012 | 56 | 33/20 | Western blot | 38% | No |
1Last name of the first author/year of publication.
SCC squamous cell carcinoma, IHC immunohistochemistry.